PMDA Outlines Weight-of-Evidence Options for Monoclonal Antibody Toxicology
Japan’s early-consideration document examines when a six-month monkey study adds useful safety information and how human-relevant evidence can contribute when no pharmacologically relevant animal species exists.
- Issuing Authority
- Pharmaceuticals and Medical Devices Agency
- Jurisdiction
- Japan
- Document Covered
- Early Consideration concerning general toxicity evaluation of conventional monoclonal antibodies, 13 May 2026; early scientific reference information.
Conventional Antibodies and Relevant Species
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) published an Early Consideration on general toxicity evaluation of monoclonal antibodies on 13 May 2026. It addresses conventional, unmodified immunoglobulin antibodies and builds on PMDA’s 2025 discussion of weight-of-evidence assessment in nonclinical safety. The document provides the agency’s thinking at an early stage and may evolve with scientific experience.
Monoclonal antibodies often have high target and species specificity, leaving monkeys as the only pharmacologically relevant animal species. PMDA cites accumulated experience suggesting that three-month studies can provide substantial safety information for conventional antibodies. The document organizes its recommendations around whether a suitable species exists and what additional information a longer study is likely to provide.
Assessing the Value of a Six-Month Study
When monkeys are the only relevant species, the assessment of a six-month study should integrate available three-month toxicology and toxicokinetic results, mechanism and pharmacological properties, information about the target and other nonclinical evidence, including NAMs. Existing clinical safety and pharmacokinetic observations and experience with other antibodies against the same target can add to the assessment.
PMDA identifies circumstances in which a six-month study is more likely to be needed. They include toxicity with an unexplained mechanism, findings that cannot be adequately monitored in humans, widespread target expression with potential effects across many organs, and a target with little prior experience on which to base a risk prediction.
If those concerns are absent, the extra information from a six-month study may be limited. The document also notes situations in which substantial immunogenicity in monkeys complicates interpretation. The decision should then consider the integrated risk assessment and the likely value of conducting the additional study.
When No Relevant Species Exists
PMDA discusses approaches for antibodies that have no adequately relevant animal species. Depending on the target, evaluation can consider transgenic models or homologous proteins, target-safety information and NAMs focused on specific anticipated risks. Target-safety assessment can integrate biological function, pathways, protein and gene expression and genetic information.
For antibodies against exogenous antigens, the main concern may lie in off-target effects rather than toxicity from the intended pharmacology. PMDA considers the value of a separate repeat-dose study in a nonrelevant species to be limited in that setting. Information from other animal studies can be used to assess important functions such as the cardiovascular and respiratory systems.
For human-specific targets or targets with inadequate animal pharmacological activity, the availability of relevant models determines what can be learned experimentally. If neither a transgenic approach nor a homologous protein is usable, PMDA emphasizes making full use of available information, including nonclinical and clinical experience with related products, within a weight-of-evidence assessment. PMDA also calls for confirmation in an animal study that there are no particular concerns about important functions, such as cardiovascular and respiratory function.
Use the Evidence in Development Discussions
The document also places general toxicology alongside tissue cross-reactivity, assessment of cytokine-release risk where appropriate and potential secondary effects associated with off-target binding. Human-relevant methods may contribute to those questions as part of the broader safety evaluation.
PMDA encourages developers to use consultation opportunities to discuss the need for long-term monkey studies and the proposed use of NAMs within an integrated safety assessment. Its case-by-case approach connects study duration and method choice to target biology, known safety findings and the protection of participants in the planned clinical program.